Blue Owl Capital Holdings portfolio
Private equity or venture capitalPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 11, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Blue Owl Capital Holdings reported a $658M portfolio of 70 companies (71 positions, counting each share class separately) to the SEC as of the end of Q2 2026. Its largest positions are SPCX, AKTS, CGEM. During the quarter it opened Capital One Financial and Artiva Biotherapeutics and exited Civeo and Ovid Therapeutics.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Blue Owl Capital Holdings has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
What changed this quarter
43 positions with a change (12 new, 11 added to, 13 trimmed, 7 sold); also, 4 entered through an IPO, 6 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedSpace Exploration TechnologiesSPCX36.3% of the portfolio
- Newly listedDeep FissionFISN2.2% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Capital One Financial+3.7 ppof portfolioNew— → 3.7%
- MapLight Therapeutics−27%fewer sharesReduced5.5% → 4.0%
- Artiva Biotherapeutics+1.3 ppof portfolioNew— → 1.3%
- Dell Technologies+137%more sharesIncreased0.6% → 2.2%
- Sagimet Biosciences+278%more sharesIncreased0.5% → 1.5%
- Cullinan Therapeutics−19%fewer sharesReduced7.4% → 4.3%
- Larimar Therapeutics+29%more sharesIncreased8.7% → 4.2%
- Viridian Therapeutics+0.7 ppof portfolioNew— → 0.7%
- Civeo−0.7 ppof portfolioSold out1.3% → —
- Ovid Therapeutics−0.6 ppof portfolioSold out1.1% → —
- Ultragenyx Pharmaceutical−40%fewer sharesReduced1.7% → 0.9%
- Pliant Therapeutics−0.6 ppof portfolioSold out1.0% → —
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Space Exploration TechnologiesSPCX36.3%
- Aktis OncologyAKTS15.0%
- Cullinan TherapeuticsCGEM4.3%
- Larimar TherapeuticsLRMR4.2%
- Nuveen Churchill Direct LendingNCDL4.0%
- MapLight TherapeuticsMPLT4.0%
- Capital One FinancialCOF3.7%
- Blue OWL CapitalOBDC3.4%
- Deep FissionFISN2.2%
- Dell TechnologiesDELL2.2%
- HolleyHLLY1.7%
- EyePointEYPT1.7%
- Sagimet BiosciencesSGMT1.5%
- Corvus PharmaceuticalsCRVS1.4%
- Artiva BiotherapeuticsARTV1.3%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 44%
- ● Industrials 38%
- ● No sector 7%
- ● Financials 4%
- ● Utilities 2%
- ● Information Technology 2%
- ● Consumer Discretionary 2%
How its portfolio changed (8 quarters)
Q2 2026: 71
Q2 2026: 79%
Q2 2026: 31.7%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
13F filings with amendments or confidential positions
- 13F Q4 2025 ↗filed Feb 9, 2026Amendment of Feb 20, 2026 (replaces the original) ↗
Declared options (5)
Besides stocks, Blue Owl Capital Holdings declared 5 calls (they gain if it rises) with a notional of $6.5M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- CALLCOMPASS PathwaysCMPS$5.2M
- CALLErascaERASnew this quarter$795K
- CALLEledon PharmaceuticalsELDNnew this quarter$285K
- CALLLarimar TherapeuticsLRMR$146K
- CALLCompass TherapeuticsCMPX$106K
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Not counted as a concentrated manager: it is a private equity or venture firm; its stocks are usually holdings that went public. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- WFM Asia (bvi)Investment firm · $663M
- Cantillon Capital ManagementInvestment firm · $665M
- BlueSpruce InvestmentsInvestment firm · $650M
- Broad Run Investment ManagementInvestment firm · $650M
- Vancity Investment Management$666M
- JB Capital PartnersInvestment firm · $646M